Skip to content
Triangle logo TriangleGet started
← Study library

NCT01008462 · REGISTRY CONDITION SEARCH

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2019-06-11

This phase II trial studies autologous peripheral blood stem cell transplant followed by donor bone marrow transplant in treating patients with high-risk Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, or chronic lymphocytic leukemia. Autologous stem cell transplantation uses the patient's stem cells and does not cause graft versus host disease (GVHD) and has a very low risk of death, while minimizing the number of cancer cells. Peripheral blood stem cell (PBSC) transplant uses stem cells from the patient or a donor and may be able to replace immune cells that were destroyed by chemotherapy. These donated stem cells may help destroy cancer cells. Bone marrow transplant known as a nonmyeloablative transplant uses stem cells from a haploidentical family donor. Autologous peripheral blood stem cell transplant followed by donor bone marrow transplant may work better in treating patients with high-risk Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, or chronic lymphocytic leukemia.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Event-Free Survival (EFS)

→

outcome · POSTED

Number of Patients With Relapsed/Progressive Disease

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Number of Patients With Grade II-IV Acute Graft-versus-Host-Disease and/or Chronic Extensive Graft-versus-Host-Disease

→

outcome · POSTED

Non-relapse Mortality (NRM)

→

outcome · POSTED

Number of Patients Who Engrafted

→

outcome · POSTED

Number of Patients Who Had Infections

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Must have the capacity to give informed consent * Detectable tumor prior to mobilization regimen * Patients with stored autologous stem cells will be allowed * Stem cells from an identical donor could be used for autologous hematopoietic cell transplant (HCT) * Marrow is the preferred source of stem cells from the HLA-haploidentical donor, however, peripheral blood mononuclear cells (PBMC) could be used as stem cell source, after clearance with the Fred Hutchinson Cancer Research Center (FHCRC) principal investigator, in the case of difficulties or contraindications to bone marrow harvest from the donor * Cross-over to other tandem autologous-allogeneic research protocol (#1409 or other appropriate protocol) will be allowed if a suitable HLA-matched related or unrelated donor is identified before receiving the allogeneic transplantation and if the patient meets the eligibility criteria of the subsequent study * Cross-over from other tandem autologous-allogeneic research protocol (#1409 or other appropriate protocol) will be allowed if the patient loses the suitable HLA-matched related or unrelated donor but has an available HLA-haploidentical donor before receiving the allogeneic transplantation and if the patient meets the eligibility criteria of the subsequent study * Lymphoma: patients with * Diagnosis of non-Hodgkin lymphoma (NHL) or Hodgkin's lymphoma (HL), of any histological grade * Refractory or relapsed disease after standard chemotherapy * High risk of early relapse following autograft alone * Waldenstrom's macroglobulinemia: must have failed 2 courses of therapy * CLL: * Patients with either a: * Diagnosis of T-cell CLL or T-cell prolymphocytic leukemia (PLL) who have failed initial chemotherapy, patients with T cell CLL or PLL or * Diagnosis of B-cell CLL, B-cell small lymphocytic lymphoma, or B-cell CLL that progressed to PLL who either: 1. Failed to meet National Cancer Institute (NCI) Working Group criteria for complete or partial response after therapy with a regimen containing fludarabine (or another nucleoside analog, e.g. 2-chlorodeoxyadenosine \[CDA\], pentostatin) or experience disease relapse within 12 months after completing therapy with a regimen containing fludarabine (or another nucleoside analog) 2. Failed any aggressive chemotherapy regimen, such as fludarabine, cyclophosphamide and rituximab (FCR), at any time point 3. Have "17p deletion" cytogenetic abnormality and relapsed at any time point after initial chemotherapy * Harvesting criteria for autologous HCT: * Previously collected PBMC may be used * Circulating CLL cells \< 5000 * Marrow involvement with CLL cells \< 50% * Multiple myeloma (MM): patients who * Have received induction therapy for a minimum of 4 cycles * In addition, patients must meet at least one of the following criteria I-IX (I-VII at time of diagnosis or pre-autograft): * Any abnormal karyotype by metaphase analysis except for isolated t(11,14), * Fluorescent in situ hybridization (FISH) translocation 4:14, * FISH translocation 14:16, * FISH deletion 17p, * Beta2 (B2)-microglobulin \> 5.5 mg/ml, * Cytogenetic hypodiploidy * Plasmablastic morphology (\>= 2%) * Recurrent or non-responsive (less than partial remission \[PR\]) MM after at least two different lines of conventional chemotherapy * Progressive MM after a previous autograft (provided stored autologous cluster of differentiation \[CD\]34 cells are available) * Plasma cell leukemia: after induction chemotherapy * DONOR: Related donors who are genotypically identical for one HLA haplotype and who may be mismatched at the HLA-A, -B, -C or DRB1 loci of the unshared haplotype with the exception of single HLA-A, -B or -C allele mismatches * DONOR: Marrow is the preferred source of stem cells from the HLA-haploidentical donor, however PBMC could be used as stem cell source, after clearance with the FHCRC principal investigator, in the case of difficulties or contraindications to bone marrow harvest from the donor * DONOR: In the case that PBMC will be used as stem cell source, ability of donors \< 18 years of age to undergo apheresis without use of a vascular access device; vein check must be performed and verified by an apheresis nurse prior to arrival at the Seattle Cancer Care Alliance (SCCA) * DONOR: Age \>= 12 years of age Exclusion Criteria: * Life expectancy severely limited by disease other than malignancy * Seropositive for the human immunodeficiency virus * Female patients who are pregnant or breastfeeding * Fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment * Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy * Patients with active non-hematological malignancies (except non-melanoma skin cancers) or those with non-hematological malignancies (except non-melanoma skin cancers) who have been rendered with no evidence of disease, but have a greater than 20% chance of having disease recurrence within 5 years * This exclusion does not apply to patients with non-hematologic malignancies that do not require therapy * Patients with fungal infection and radiological progression after receipt of amphotericin B or active triazole for greater than 1 month * Symptomatic coronary artery disease or ejection fraction \< 40% or other cardiac failure requiring therapy (or, if unable to obtain ejection fraction, shortening fraction of \< 26%); ejection fraction is required if the patient has a history of anthracyclines or history of cardiac disease; patients with a shortening fraction \< 26% may be enrolled if approved by a cardiologist * Corrected diffusion capacity of the lungs for carbon monoxide (DLCO) \< 50% of predicted, forced expiratory volume in one second (FEV1) \< 50% of predicted, and/or receiving supplementary continuous oxygen; the FHCRC principal investigator (PI) of the study must approve of enrollment of all patients with pulmonary nodules * Patient with clinical or laboratory evidence of liver disease will be evaluated for the cause of liver disease, its clinical severity in terms of liver function, bridging fibrosis, and the degree of portal hypertension; the patient will be excluded if he/she is found to have fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin \> 3 mg/dL, and symptomatic biliary disease * Karnofsky score \< 50% for adult patients * Lansky play-performance score \< 40 for pediatric patients * Patient with poorly controlled hypertension despite multiple antihypertensives * DONOR: Donor-recipient pairs in which the HLA-mismatch is only in the host-versus-graft (HVG) direction * DONOR: Infection with human immunodeficiency virus (HIV) * DONOR: Weight \< 20 kg * DONOR: A positive anti-donor cytotoxic crossmatch
healthy Volunteers
false
maximum Age
75 Years
sex
ALL
std Ages
  1. CHILD
  2. ADULT
  3. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    See Detailed Description
    intervention Names
    1. Procedure: Allogeneic Bone Marrow Transplantation
    2. Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
    3. Procedure: Autologous Hematopoietic Stem Cell Transplantation
    4. Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation
    5. Drug: Carmustine
    6. Drug: Cyclophosphamide
    7. Drug: Cytarabine
    8. Drug: Etoposide
    9. Drug: Fludarabine Phosphate
    10. Other: Laboratory Biomarker Analysis
    11. Drug: Melphalan
    12. Drug: Mycophenolate Mofetil
    label
    Treatment (autologous HCT, donor HCT)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Treatment (autologous HCT, donor HCT)
    description
    Undergo donor HCT
    name
    Allogeneic Bone Marrow Transplantation
    other Names
    1. Allo BMT
    2. Allogeneic BMT
    type
    PROCEDURE
  2. arm Group Labels
    1. Treatment (autologous HCT, donor HCT)
    description
    Undergo donor HCT
    name
    Allogeneic Hematopoietic Stem Cell Transplantation
    other Names
    1. Allogeneic Hematopoietic Cell Transplantation
    2. Allogeneic Stem Cell Transplantation
    3. HSC
    4. HSCT
    type
    PROCEDURE
  3. arm Group Labels
    1. Treatment (autologous HCT, donor HCT)
    description
    Undergo autologous PBSC transplant
    name
    Autologous Hematopoietic Stem Cell Transplantation
    other Names
    1. Autologous Hematopoietic Cell Transplantation
    2. autologous stem cell transplantation
    type
    PROCEDURE
  4. arm Group Labels
    1. Treatment (autologous HCT, donor HCT)
    description
    Undergo autologous-donor tandem HCT
    name
    Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation
    other Names
    1. auto-allo HCT
    type
    PROCEDURE
  5. arm Group Labels
    1. Treatment (autologous HCT, donor HCT)
    description
    Given IV
    name
    Carmustine
    other Names
    1. BCNU
    2. Becenum
    3. Becenun
    4. BiCNU
    5. Bis(chloroethyl) Nitrosourea
    6. Bis-Chloronitrosourea
    7. Carmubris
    8. Carmustin
    9. Carmustinum
    10. FDA 0345
    11. Gliadel
    12. N,N'-Bis(2-chloroethyl)-N-nitrosourea
    type
    DRUG
  6. arm Group Labels
    1. Treatment (autologous HCT, donor HCT)
    description
    Given IV
    name
    Cyclophosphamide
    other Names
    1. (-)-Cyclophosphamide
    2. 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate
    3. Carloxan
    4. Ciclofosfamida
    5. Ciclofosfamide
    6. Cicloxal
    7. Clafen
    8. Claphene
    9. CP monohydrate
    10. CTX
    11. CYCLO-cell
    12. Cycloblastin
    type
    DRUG
  7. arm Group Labels
    1. Treatment (autologous HCT, donor HCT)
    description
    Given IV
    name
    Cytarabine
    other Names
    1. .beta.-Cytosine arabinoside
    2. 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
    3. 1-.beta.-D-Arabinofuranosylcytosine
    4. 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone
    5. 1-Beta-D-arabinofuranosylcytosine
    6. 1.beta.-D-Arabinofuranosylcytosine
    7. 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-
    8. 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-
    9. Alexan
    10. Ara-C
    11. ARA-cell
    12. Arabine
    type
    DRUG
  8. arm Group Labels
    1. Treatment (autologous HCT, donor HCT)
    description
    Given IV
    name
    Etoposide
    other Names
    1. Demethyl Epipodophyllotoxin Ethylidine Glucoside
    2. EPEG
    3. Lastet
    4. Toposar
    5. Vepesid
    6. VP 16-213
    7. VP-16
    8. VP-16-213
    type
    DRUG
  9. arm Group Labels
    1. Treatment (autologous HCT, donor HCT)
    description
    Given IV
    name
    Fludarabine Phosphate
    other Names
    1. 2-F-ara-AMP
    2. 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-
    3. Beneflur
    4. Fludara
    5. SH T 586
    type
    DRUG
  10. arm Group Labels
    1. Treatment (autologous HCT, donor HCT)
    description
    Correlative study
    name
    Laboratory Biomarker Analysis
    type
    OTHER
  11. arm Group Labels
    1. Treatment (autologous HCT, donor HCT)
    description
    Given IV
    name
    Melphalan
    other Names
    1. Alanine Nitrogen Mustard
    2. CB-3025
    3. L-PAM
    4. L-Phenylalanine Mustard
    5. L-sarcolysin
    6. L-Sarcolysin Phenylalanine mustard
    7. L-Sarcolysine
    8. Melphalanum
    9. Phenylalanine Mustard
    10. Phenylalanine nitrogen mustard
    11. Sarcoclorin
    12. Sarkolysin
    type
    DRUG
  12. arm Group Labels
    1. Treatment (autologous HCT, donor HCT)
    description
    Given PO
    name
    Mycophenolate Mofetil
    other Names
    1. Cellcept
    2. MMF
    type
    DRUG
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
16
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Number of patients surviving without relapsed/progressive disease
    measure
    Event-Free Survival (EFS)
    time Frame
    1 Year post-autograft
secondary Outcomes
  1. description
    Relapse/Progression defined as: Nodes, liver, and/or spleen ≥50% increased or new by physical exam / imaging studies. Circulating lymphocytes ≥50% increased by morphology and/or flow cytometry. Richter's transformation by lymph node biopsy .
    measure
    Number of Patients With Relapsed/Progressive Disease
    time Frame
    1 year post-autograft
  2. description
    Number of patients surviving one year post-autograft
    measure
    Overall Survival
    time Frame
    1 year post-autograft
  3. description
    aGVHD The diagnosis of aGVHD is identified through various stages and grading of the disease related to Skin (Rash), Gut (Diarrhea, Nausea/vomiting and/or anorexia) and the liver (Bilirubin) assessed by severity and grading scale outlined in the section Grafts vs Hosts by Sullivan (1999). GVHD Grades Grade I: 1-2 Skin Rash; No gut or liver involvement Grade II: Stage 1-3 Skin rash; Stage 1 gut and/or stage 1 liver involvement Grade III: Stage 2-4 gut involvement and/or stage 2-4 liver involvement with or without rash Grade IV: Pattern and severity of GVHD similar to grade 3 with extreme constitutional symptoms or death CGVHD The diagnosis of cGVHD requires at least one manifestation that is distinctive for chronic GVHD as opposed to acute GVHD. In all cases, infection and others causes must be ruled out in the differential diagnosis of chronic GVHD.
    measure
    Number of Patients With Grade II-IV Acute Graft-versus-Host-Disease and/or Chronic Extensive Graft-versus-Host-Disease
    time Frame
    1 year post-allograft,
  4. description
    Number of patients with non-relapse mortalities.
    measure
    Non-relapse Mortality (NRM)
    time Frame
    200 days and 1 Year post-allograft
  5. description
    Number of patients with donor engraftment.
    measure
    Number of Patients Who Engrafted
    time Frame
    Day 84 post-allograft
  6. description
    Number of patients who had infections.
    measure
    Number of Patients Who Had Infections
    time Frame
    1 Year post-autograft
Full study description
brief Summary
This phase II trial studies autologous peripheral blood stem cell transplant followed by donor bone marrow transplant in treating patients with high-risk Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, or chronic lymphocytic leukemia. Autologous stem cell transplantation uses the patient's stem cells and does not cause graft versus host disease (GVHD) and has a very low risk of death, while minimizing the number of cancer cells. Peripheral blood stem cell (PBSC) transplant uses stem cells from the patient or a donor and may be able to replace immune cells that were destroyed by chemotherapy. These donated stem cells may help destroy cancer cells. Bone marrow transplant known as a nonmyeloablative transplant uses stem cells from a haploidentical family donor. Autologous peripheral blood stem cell transplant followed by donor bone marrow transplant may work better in treating patients with high-risk Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, or chronic lymphocytic leukemia.
detailed Description
PRIMARY OBJECTIVES: I. Event-free survival (EFS) at 1-year after autograft. SECONDARY OBJECTIVES: I. Relapse rates at 1-year after autograft. II. Overall survival (OS) at 1-year after autograft. III. Incidence of grades II-IV acute GVHD and chronic extensive GVHD. IV. Non-relapse mortality (NRM) at 200 days and 1 year after allograft. V. Donor engraftment at day +84. VI. Incidence of infections. OUTLINE: CONDITIONING REGIMEN 1 (lymphoma, Waldenstrom macroglobulinemia, or chronic lymphocytic leukemia \[CLL\] with no dose limiting radiation or significant comorbidities: Patients receive cyclophosphamide intravenously (IV) on days -6 and -5. Patients undergo high-dose total body irradiation (TBI) twice daily (BID) on days -3 to -1. CONDITIONING REGIMEN 2 (lymphoma, Waldenstrom Macroglobulinemia, CLL, with prior dose-limiting radiation, or significant comorbidities): Patients receive carmustine IV on day -7, etoposide IV BID on days -6 to -3, cytarabine IV BID on days -6 to -3, and melphalan IV on day -2. CONDITIONING REGIMEN 3 (multiple myeloma or plasma cell leukemia, with no significant renal insufficiency or other significant comorbidities): Patients receive high-dose melphalan IV on day -2. CONDITIONING REGIMEN 4 (multiple myeloma or plasma cell leukemia, with significant renal insufficiency or other significant comorbidities): Patients receive lessened dose of melphalan IV on day -2. PBSC TRANSPLANTATION: All patients undergo autologous PBSC transplantation on day 0. WAITING INTERVAL: Between 40 and 120 days. NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV once daily (QD) on days -6 to -2 and cyclophosphamide IV QD on days -6 to -5 and day 3. Patients infused with donor's peripheral blood stem cells will additionally receive cyclophosphamide IV on day 4. Patients undergo low-dose TBI on day -1. ALLOGENEIC BONE MARROW TRANSPLANTATION: Patients undergo donor bone marrow transplantation on day 0. GRAFT VERSUS HOST DISEASE PROPHYLAXIS: Beginning on day 4, patients receive tacrolimus orally (PO) or IV and taper beginning on day 86 if no graft-versus-host disease. Patients also receive mycophenolate mofetil PO thrice daily (TID) on days 4 - 35. PERIPHERAL BLOOD COUNT SUPPORT: Patients receive filgrastim (G-CSF) IV or subcutaneously (SC) beginning from day 4 and continue till blood counts recover. ALLOGENEIC PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC) TRANSPLANTATION: Patients undergo donor PBMC transplantation on day 0. GRAFT VERSUS HOST DISEASE PROPHYLAXIS: Beginning on day 5, patients receive tacrolimus orally (PO) or IV and taper beginning on day 86 if no graft-versus-host disease. Patients also receive mycophenolate mofetil PO thrice daily (TID) on days 5 - 35. PERIPHERAL BLOOD COUNT SUPPORT: Patients receive filgrastim IV or SC beginning from day 5 and continue till blood counts recover. After completion of study treatment, patients are followed up annually for 5 years.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-5d3cbf7d342bbac587ed
      requested nct id
      NCT01008462
      primary nct id
      NCT01008462
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      75c704e5643429421d617bf1b7514a80748e915328687162d20504e752f4e259
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-5d3cbf7d342bbac587ed
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01008462
      occurrences
      1. context exact
        NCT01008462
        end
        11
        exact text
        NCT01008462
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/473/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      772f453e88677277c2143eca1410837d0238105714ecd4d5dfef27d6af783048
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-bcb4c9e785a5a8e48799
      requested nct id
      NCT01008462
      primary nct id
      NCT01008462
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
      payload sha256
      964be0014907054ddb9943aec8b35aa54aed7d2d54dbef2725931b29702ede56
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-bcb4c9e785a5a8e48799
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01008462
      occurrences
      1. context exact
        NCT01008462
        end
        11
        exact text
        NCT01008462
        start
        0
      offset unit
      unicode_code_points
      query cond
      Peripheral T-Cell Non-Hodgkin Lymphoma
      query disease state id
      ds-peripheral-t-cell-non-hodgkin-lymphoma
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-peripheral-t-cell-non-hodgkin-lymphoma-000.json
      source file sha256
      e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
      source json pointer
      /studies/57/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      772f453e88677277c2143eca1410837d0238105714ecd4d5dfef27d6af783048

    Preserved source evidence · Not medical advice